Diagnosis and management of menopause: Summary of NICE guidance

BMJ (Online)

Volumn 351, Issue , 2015, Pages

  Sarri, Grammati ^a   Davies, Melanie ^b   Lumsden, Mary Ann ^c  

^a ROYAL COLLEGE OF OBSTETRICIANS AND GYNAECOLOGISTS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; CIMICIFUGA RACEMOSA EXTRACT; ESTROGEN; FOLLITROPIN; GESTAGEN; ISOFLAVONE; LUBRICATING AGENT;

ANXIETY DISORDER; ARTICLE; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; COGNITIVE THERAPY; COUNSELING; DEMENTIA; HEALTH CARE PLANNING; HETEROZYGOTE; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; MEDICAL INFORMATION; MENOPAUSAL SYNDROME; MOOD DISORDER; NATIONAL HEALTH ORGANIZATION; NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE; NON INSULIN DEPENDENT DIABETES MELLITUS; ONCOGENE; OSTEOPOROSIS; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SEX HORMONE DETERMINATION; SYSTEMATIC REVIEW (TOPIC); UNITED KINGDOM; UROGENITAL ATROPHY; UROGENITAL TRACT DISEASE; VAGINAL DRYNESS; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM; WOMEN'S HEALTH; ANAMNESIS; BREAST NEOPLASMS; FEMALE; MENOPAUSE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT REFERRAL; PHYSIOLOGY; PROCEDURES; PSYCHOLOGY; QUALITY OF LIFE; RISK ASSESSMENT; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; HORMONE REPLACEMENT THERAPY; HUMANS; MEDICAL HISTORY TAKING; MENOPAUSE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; QUALITY OF LIFE; REFERRAL AND CONSULTATION; RISK ASSESSMENT;

EID: 84951727949     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h5746     Document Type: Article

References (11)

1. Avis NE, Crawford SL, Greendale G, et al; Study of Women's Health Across the Nation. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015;175:531-9.
2. Blümel JE, Chedraui P, Baron G, et al. A large multinational study of vasomotor symptom prevalence, duration, and impact on quality of life in middle-aged women. Menopause 2011;18:778-85.
3. Lumsden M. The hormone replacement therapy controversy. BJOG 2005;112:689-91.
4. Kreiger N, Löwy I, Aronowitz R, et al. Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical, and advocacy perspectives. J Epidemiol Community Health 2005;59:740-8.
5. National Institute for Health and Care Excellence. Menopause: diagnosis and management of menopause. (NICE guideline 23.) 2015. www.nice.org.uk/guidance/ng23.
6. National Institute for Health and Care Excellence. Depression in adults: recognition and management. (Clinical guideline 90.) 2009. www.nice.org.uk/guidance/cg90.
7. National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. (NICE guideline 12.) 2015. www.nice.org.uk/guidance/ng12.
8. National Institute for Health and Care Excellence. Early and locally advanced breast cancer: diagnosis and treatment. (Clinical guideline 80.) 2009. www.nice.org.uk/guidance/cg80.
9. National Institute for Health and Care Excellence. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. (Clinical guideline 164.) 2013. www.nice.org.uk/guidance/cg164.
10. Health and Social Care Information Centre. Prescription cost analysis-England, 2010. 2011. www.hscic.gov. uk/catalogue/PUB02274.
11. Chiechi LM, Berardesca C, Lobascio A, et al. Postmenopausal users of long-term hormonal replacement therapy: social-cultural features. Clin Exp Obstet Gynecol 1999;26:88-90.